ZYNE Stock Summary

• Zynerba Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 7.15% of US listed stocks.
• ZYNE's price/sales ratio is 2,006.9; that's higher than the P/S ratio of 99.84% of US stocks.
• Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ZYNE comes in at -43.59% -- higher than that of merely 8.4% of stocks in our set.
• Stocks with similar financial metrics, market capitalization, and price volatility to Zynerba Pharmaceuticals Inc are NK, CBMG, ARDX, PSTI, and AUPH.
• ZYNE's SEC filings can be seen here. And to visit Zynerba Pharmaceuticals Inc's official web site, go to www.zynerba.com.